Pacing System Weans Patients Off Mechanical Ventilation
By HospiMedica International staff writers Posted on 19 May 2020 |
Image: The Lungpacer Diaphragmatic Pacing Therapy System (DPTS) (Photo courtesy of Lungpacer Medical)
An innovative, non-implanted device helps forestall invasive mechanical ventilation weaning failure, including for COVID-19 patients.
The Lungpacer Medical (Vancouver, Canada) Diaphragmatic Pacing Therapy System (DPTS) is a minimally invasive, temporary, transvenous phrenic-stimulation system that is delivered via a central venous catheter (CVC). DPTS delivers not only fluids and medications, but also provides the ability to activate the diaphragm muscle via transvenous phrenic nerve stimulation. The neural stimulation is intended to strengthen the weakened diaphragm--atrophied due to ventilator induced diaphragm dysfunction (VIDD)--and help patients wean off the ventilator more rapidly.
Reducing time on the ventilator decreases the risk of ventilator-induced lung injury (VILI), secondary pneumonias, and poor patient outcomes associated with prolonged mechanical ventilation. It also frees up intensive care unit (ICU) beds, hospital resources, and mechanical ventilators, effectively reducing ventilator burden by a projected 26% during the COVID-19 pandemic crisis. As a result, the Lungpacer DPTS was authorized by the U.S. Food and Drug Administration (FDA) for emergency use for the duration of the pandemic, unless authorization is revoked or terminated sooner.
“The COVID-19 pandemic, also known as SARS-COVID-2, has stimulated tremendous innovation to improve outcomes for these patients,” said Doug Evans, CEO of Lungpacer Medical. “I am very proud of the Lungpacer team, who have worked diligently to make this therapy available in a very short period of time. We are excited for the opportunity to provide healthcare professionals with access to Lungpacer therapy to help their critically ill patients.”
“Hospital resources around the world have been under significant strain during the COVID-19 pandemic, and ICU beds and mechanical ventilators have been at peak demand,” said pulmonologist Ali Ataya, MD, of University of Florida Health (Gainesville, FL, USA). “This novel therapy has the potential to wean patients earlier from the ventilator and free up resources during these difficult times. We are looking forward as an institution to start using this technology to help our patients during this pandemic.”
Related Links:
Lungpacer Medical
The Lungpacer Medical (Vancouver, Canada) Diaphragmatic Pacing Therapy System (DPTS) is a minimally invasive, temporary, transvenous phrenic-stimulation system that is delivered via a central venous catheter (CVC). DPTS delivers not only fluids and medications, but also provides the ability to activate the diaphragm muscle via transvenous phrenic nerve stimulation. The neural stimulation is intended to strengthen the weakened diaphragm--atrophied due to ventilator induced diaphragm dysfunction (VIDD)--and help patients wean off the ventilator more rapidly.
Reducing time on the ventilator decreases the risk of ventilator-induced lung injury (VILI), secondary pneumonias, and poor patient outcomes associated with prolonged mechanical ventilation. It also frees up intensive care unit (ICU) beds, hospital resources, and mechanical ventilators, effectively reducing ventilator burden by a projected 26% during the COVID-19 pandemic crisis. As a result, the Lungpacer DPTS was authorized by the U.S. Food and Drug Administration (FDA) for emergency use for the duration of the pandemic, unless authorization is revoked or terminated sooner.
“The COVID-19 pandemic, also known as SARS-COVID-2, has stimulated tremendous innovation to improve outcomes for these patients,” said Doug Evans, CEO of Lungpacer Medical. “I am very proud of the Lungpacer team, who have worked diligently to make this therapy available in a very short period of time. We are excited for the opportunity to provide healthcare professionals with access to Lungpacer therapy to help their critically ill patients.”
“Hospital resources around the world have been under significant strain during the COVID-19 pandemic, and ICU beds and mechanical ventilators have been at peak demand,” said pulmonologist Ali Ataya, MD, of University of Florida Health (Gainesville, FL, USA). “This novel therapy has the potential to wean patients earlier from the ventilator and free up resources during these difficult times. We are looking forward as an institution to start using this technology to help our patients during this pandemic.”
Related Links:
Lungpacer Medical
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration